Virtual Library
Start Your Search
F. Vinas
Author of
-
+
P3.02b - Poster Session with Presenters Present (ID 494)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 12/07/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P3.02b-127 - NSCLC Patients Harboring HER2 Mutation: Clinical Characteristics and Management in Real World Setting. EXPLORE GFPC 02-14 (ID 4629)
14:30 - 14:30 | Author(s): F. Vinas
- Abstract
Background:
HER 2 (Human epidermal growth factor 2) mutation (exon-20 insertion) is a rare oncogenic driver in Non Small Cell Lung Cancer (NSCLC) (1%) and few data are published on the management of these patients outside patients included in clinical trial. Objective: to investigate clinical characteristics and management of these patients in real world setting
Methods:
multicentric inclusion of pts with a diagnosis of NSCLC harboring HER 2 mutations between January 2012 and December 2014, collection of demographic and clinical characteristics, risk factors, Progression free survival (PFS), Overall Survival (OS), mode of progression and therapeutic management
Results:
30 patients recruited in 17 centers: 20 (66,6%) female; age: 65,2 ± 12,1 years; PS 0/1 at diagnosis: 92,5 %; current/former smokers: 0/8(27,6%); adenocarcinoma: 93,3%; Stage at diagnosis 4-3/2-1: 93.1%/6,9%: co-mutations ALK n=1, RET n=1. Two-years overall survival (OS) 44,0% [CI :27,1 ; 71,5%] (early stage : 2-years OS : 100%). Management and Outcomes of stage IV (n=22): 82% received a first line platin based doublets With an overall response rate (ORR) and Progression Free Survival (PFS) of 61,5%, and 6.7 months (CI 5.6 ;19.0); 55% received a . second line treatment with an ORR and PFS of 36,4% and 3,4 months (CI 1,8;12,7); Two-years-OS was 27,2 %(CI:11,7;63,2%) and median OS survival 10,7 months (CI not research). .
Conclusion:
In this real world analysis, the majority of NSCLC patients with HER2 mutation were women, nonsmokers, adenocarcinoma and appears to have a same survival that NSCLC patients without oncogenic driver. Clinical trial information: Supported by an academic grant from Lilly, Astra Zeneca, boehringer ingelheim
-
+
P3.02c - Poster Session with Presenters Present (ID 472)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 12/07/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P3.02c-089 - ImmunoCHIC: A Prospective Nivolumab Monotherapy Cohort in Advanced Non-Small Cell Lung Cancer Patients in Routine Clinical Practice (ID 5839)
14:30 - 14:30 | Author(s): F. Vinas
- Abstract
Background:
in France, in May 2015, Nivolumab early access program was established for patients with advanced NSCLC progressing during or after platinum-based chemotherapy. There is little evidence of Nivolumab use out of clinical trials. We report here one year of Nivolumab use in a French Universitary hospital.
Methods:
Observational prospective review of patients with advanced NSCLC treated with Nivolumab monotherapy (3 mg/kg/2weeks) in our center, in routine clinical practice. Patients in clinical trial were excluded. Analyze was done on clinico-pathological features, tolerance and outcomes.
Results:
63 patients were included (men: 76.1%, age: 65 (range: 40–78), squamous: 33.3%; smoker: 93.7%%, EGFR/ALK negatives: 98.4%, unknown PDL1: 70%; at least one significant comorbidity: 54%; performans status 0/1/2: 34%/49%/17%; cerebral metastasis: 38%; nivolumab as second, third and more than third lines: 38%/38%/24%. Median number of nivolumab cycles: 6 (1-24), more than 12 cycles: 20.6% Disease control rate : 59% (3 complete responses) ; Clinically significant adverse event: 13 (20%) patients (asthenia: 4 patients, grade 2 to 4 colitis: 3 patients, pneumoniae: 3 patients, nephritis: 1 patient). After Nivolumab, 50% of the patients received an another systemic therapy. Two patients were able to go back to work.
Conclusion:
In real life setting, nivolumab had the efficacy level reported by pivotal clinical trial but with a higher rate of clinically significant adverse events, particularly colitis.
